Month: August 2025

Completes Previously Announced Merger with Windstream Provides Consolidated 2025 Outlook for Combined CompanyNet Loss of $10.7 Million for the Second Quarter Net Loss of $0.04 Per Diluted Common Share for the Second Quarter AFFO of $0.36 Per Diluted Common Share for the Second QuarterLITTLE ROCK, Ark., Aug. 05, 2025 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced its results for the second quarter 2025. The second quarter results and highlights presented in this release are for legacy Uniti Group Inc. (now known as Uniti Group LLC and a subsidiary of the Company) prior to the previously announced business combination with Windstream, which closed August 1, 2025, as discussed in greater detail below. “This is an exciting time for Uniti as we enter a new chapter in the Company’s history...

LAKEWOOD, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q26”) ended June 30, 2025 (amounts in thousands). First quarter FY26 compared to first quarter FY25:Revenues increased 2.4% Non-GAAP core organic revenues1 growth was 0.4% Operating income decreased 45.1% to $3,064 primarily due to the impacts of FX and non-cash stock-based compensation expense Non-GAAP adjusted operating income (“AOI”) excluding unusual items2 decreased 15.9% and was 21.7% as a percentage of revenues   We operate our business in four divisions: Sterilization and Disinfection Control (“SDC”), Clinical Genomics (“CG”), Biopharmaceutical Development (“BPD”),...

— Management to host investor conference call today, August 5th, at 8:30am ET — MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights:Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid stent system Commenced commercial launch of the CGuard Prime carotid stent system in the U.S. Market Raised $58 million in gross proceeds from an equity private placement and the exercise of existing warrants to advance growth initiatives Received CE Mark approval under the European Medical Device Regulation (MDR) for CGuard Prime...

Invest for Growth Success with First Half New Business Wins of $47 million and Announcement of Organic Investment of $25 million COLUMBUS, Ohio, Aug. 05, 2025 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reports financial and operating results for the fiscal periods ended June 30, 2025. David Duvall, the Company’s President and Chief Executive Officer, said, “I am proud of our team’s disciplined execution in our ability to maintain gross margins with sales being down in our two current major markets: Truck and Powersports,...

Demand Recovery and Strategic Initiatives Drove Revenue Above Expectations Book-to-Bill was Approximately One as Bookings Also Remained Strong MARLBOROUGH, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the second quarter ended June 30, 2025.  Three Months Ended June 30,           Six Months Ended June 30,        (In millions, except per share data and percentages)   2025       2024       Change       2025       2024       Change  Revenue $ 250.7     $ 257.6       (3 )%   $ 478.5     $ 509.7       (6 )%Gross margin   37.3 %     37.3 %             38.3 %     38.0 %        Operating income $ 0.1     $ 12.0       (99 )%   $ 1.9     $ 31.1       (94 )%Operating margin   — %     4.7 %             0.4 %     6.1 %        Net income $ 6.6     $ 20.2       (67 )%   $ 10.4     $ 44.3       (77 )%Earnings...

Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025 Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913 All three clinical programs (CRB-701, CRB-913, CRB-601) on track for data readouts in the second half of 2025NORWOOD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended June 30, 2025. “The second half of 2025 is shaping up to be impactful, with scheduled data readouts anticipated for all three of our clinical programs,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We have been very pleased with the strong rate of enrollment in the CRB-701 study and...

Second quarter net income of $9.7 millionSecond quarter Adjusted EBITDA of $28.0 millionDredging backlog of $1 billion at June 30, 2025 HOUSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (Nasdaq: GLDD), the largest provider of dredging services in the United States, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 HighlightsRevenue was $193.8 million Total operating income was $17.1 million Net income was $9.7 million Adjusted EBITDA was $28.0 million Backlog as of June 30, 2025, was $1.0 billionManagement Commentary Lasse Petterson, President and Chief Executive Officer, commented, “Great Lakes delivered a solid second quarter, driven by strong project execution and high equipment utilization. We ended the quarter...

Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints On track to share pivotal trial results from PEAK in GIST and APEX in AdvSM in 2H 2025 $453 million in pro-forma cash sufficient to fund operations through anticipated launch and into 2027; includes proceeds from upsized $230 million public offering in July 2025 WALTHAM, Mass. and BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2025. “We were thrilled to announce bezuclastinib’s impressive performance in the SUMMIT...